Abstract
A liquid biopsy may select patients with metastatic colorectal cancer who are good candidates for additional anti-EGFR therapy after developing resistance to it earlier in their treatment regimen. In a phase II trial, patients who received panitumumab based on an absence of resistance mutations in circulating tumor DNA had a 30% response rate to the anti-EGFR agent.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
